Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · IEX Real-Time Price · USD
1.010
-0.050 (-4.72%)
At close: Apr 25, 2024, 4:00 PM
1.030
+0.020 (1.98%)
After-hours: Apr 25, 2024, 6:28 PM EDT
Xilio Therapeutics Stock Forecast
XLO's stock price has decreased by -68.83% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 7.00, which predicts an increase of 593.07% from the current stock price of 1.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 30, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for XLO is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +593.07% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +593.07% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +890.10% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +593.07% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,187.13% | Nov 10, 2022 |
Financial Forecast
Revenue This Year
10.10M
Revenue Next Year
25.25M
from 10.10M
Increased by 150.00%
EPS This Year
-1.77
from -2.78
EPS Next Year
-1.40
from -1.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.5M | 78.8M | 13.1M | 24.1M | 284.1M |
| Avg | 10.1M | 25.3M | 4.2M | 12.1M | 139.2M |
| Low | n/a | n/a | n/a | 980,000 | 5.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 679.7% | -48.0% | 471.9% | 2,251.6% |
| Avg | - | 150.0% | -83.3% | 187.1% | 1,052.3% |
| Low | - | - | - | -76.7% | -58.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.83 | -0.04 | -0.77 |
| Avg | -1.77 | -1.40 | -1.57 |
| Low | -2.42 | -1.96 | -1.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.